Axsome Therapeutics (NASDAQ:AXSM) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research report released on Tuesday,Benzinga reports. They currently have a $190.00 price target on the stock.

Several other analysts also recently commented on AXSM. Royal Bank of Canada reaffirmed an “outperform” rating and set a $139.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, January 29th. Deutsche Bank Aktiengesellschaft assumed coverage on Axsome Therapeutics in a research note on Tuesday. They set a “buy” rating and a $176.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 price objective on shares of Axsome Therapeutics in a research report on Monday. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Leerink Partners lifted their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a report on Monday. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $145.80.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $132.20 on Tuesday. The company’s 50 day simple moving average is $95.28 and its 200-day simple moving average is $92.07. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $134.19. The firm has a market cap of $6.41 billion, a PE ratio of -20.25 and a beta of 1.05. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same period in the previous year, the business posted ($1.32) earnings per share. As a group, equities analysts predict that Axsome Therapeutics will post -4.7 EPS for the current year.

Institutional Trading of Axsome Therapeutics

Several large investors have recently bought and sold shares of the company. Assetmark Inc. purchased a new stake in shares of Axsome Therapeutics in the 4th quarter worth about $52,000. R Squared Ltd acquired a new position in Axsome Therapeutics during the fourth quarter worth about $64,000. KBC Group NV lifted its holdings in shares of Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after purchasing an additional 385 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after purchasing an additional 318 shares during the last quarter. Finally, Moors & Cabot Inc. purchased a new position in shares of Axsome Therapeutics during the 3rd quarter worth approximately $200,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.